Description

PIRFENOID 200 is a prescription medicine containing Pirfenidone 200 mg, specifically developed to manage Idiopathic Pulmonary Fibrosis (IPF), a progressive and chronic lung condition characterized by scarring of lung tissues. This scarring leads to stiffness, reduced oxygen transfer, and difficulty in breathing. Pirfenidone is an antifibrotic and anti-inflammatory agent that slows down the progression of lung fibrosis, improving patients’ quality of life and lung function. PIRFENOID 200, manufactured under stringent quality standards, is a trusted option for patients diagnosed with IPF, offering a combination of efficacy, safety, and ease of use. Uses PIRFENOID 200 is primarily used for the treatment of: Idiopathic Pulmonary Fibrosis (IPF): Slows disease progression by reducing lung tissue scarring. Pulmonary Fibrosis due to other causes: Used under medical supervision for certain types of progressive fibrotic lung diseases. Prevention of further lung damage: Helps maintain lung function and improves exercise tolerance in affected patients. By targeting both inflammation and fibrosis, PIRFENOID 200 provides a holistic approach to managing lung damage and supporting respiratory health. Benefits 1. Slows Disease Progression Pirfenidone inhibits fibroblast proliferation and collagen synthesis, reducing the rate of lung scarring and maintaining better respiratory function. 2. Anti-Inflammatory Action It helps in controlling inflammation in lung tissues, reducing further damage and associated symptoms such as cough and breathlessness. 3. Improves Quality of Life By slowing disease progression, PIRFENOID 200 allows patients to maintain mobility, perform daily activities, and manage symptoms more effectively. 4. Clinically Proven Pirfenidone is supported by multiple clinical studies demonstrating its efficacy in reducing the decline of lung function and improving survival in IPF patients. 5. Easy-to-Administer Tablet The 200 mg tablet ensures convenient dosing and supports treatment adherence for long-term therapy. Dosage Recommended Dose: The usual starting dose is one 200 mg tablet three times daily, which may be titrated based on tolerance and physician guidance. Administration: Take the tablet after meals with water to reduce gastrointestinal discomfort. Titration Schedule: Doctors may gradually increase the dose over several weeks to minimize side effects. Important: Do not alter the dose without consulting your physician. Regular monitoring of liver function and lung function is recommended during treatment. Side Effects PIRFENOID 200 is generally well tolerated. Some common side effects include: Nausea or vomiting Loss of appetite Fatigue or dizziness Rash or skin sensitivity to sunlight Diarrhea Serious Side Effects (Rare) Liver enzyme elevation (requires monitoring) Severe allergic reactions, including rash or swelling Shortness of breath or worsening respiratory symptoms Patients should immediately contact their healthcare provider if serious or persistent side effects occur. Precautions and Warning Liver Disorders: Monitor liver function regularly; dosage adjustment may be required. Kidney Impairment: Use cautiously in patients with renal dysfunction. Sun Exposure: Pirfenidone may increase photosensitivity; use sunscreen and protective clothing. Pregnancy and Breastfeeding: Use only under medical supervision; safety has not been fully established. Drug Interactions: Inform your doctor about other medications, especially antifungals, antibiotics, or immunosuppressants. Avoid Self-Medication: Only take PIRFENOID 200 under medical guidance, with regular check-ups. Conclusion PIRFENOID 200, containing Pirfenidone 200 mg, is a clinically proven and reliable treatment for Idiopathic Pulmonary Fibrosis and related fibrotic lung conditions. By slowing lung scarring, reducing inflammation, and improving quality of life, it provides patients with a meaningful approach to managing this chronic condition. When taken as prescribed by a physician, PIRFENOID 200 helps preserve lung function, supports daily activity, and offers hope for better long-term outcomes, making it a trusted option for patients living with progressive pulmonary fibrosis.